Rubicon Facebook Rubicon Linkedin

Rubicon Research acquires Meditab Specialities Ltd’s oral liquid and nasal inhalers manufacturing facility in Satara, Maharashtra

Thane, Mumbai (India), July 8, 2021

Today, Rubicon Research Private Limited, a leading specialty pharmaceutical company, announced the acquisition of Meditab Specialities Limited’s oral liquid dosage and nasal product manufacturing facility located in Satara, Maharashtra. Meditab Specialities Limited is a wholly owned subsidiary of Cipla Limited.

The Satara facility is a state-of-the-art cGMP compliant and MHRA (UK) inspected production site that enables a strong and diverse pipeline of oral liquids for Rubicon Research. The company will seek additional regulatory approvals at the Satara site, including from the US FDA.

“The acquisition of an outstanding oral liquid and nasal inhalers manufacturing facility advances our plan to offer a wider portfolio to our customers. These capabilities combined with our R&D expertise strengthens our ability to offer best-in-class drug products across dosage forms, which will benefit patients around the world. On behalf of Rubicon Research, I welcome our new colleagues and am confident that together we can continue to grow and make Rubicon Research one of the top 10 specialty generic pharmaceutical companies in the world,” said Parag Sancheti, Chief Executive Officer, Rubicon Research.

About Rubicon Research Pvt Ltd
Rubicon Research is an IP led, specialty pharmaceutical company that develops, manufactures and commercializes its value-added formulations for the global market. The company leverages its proprietary technologies and specialized formulation development skills to provide solutions to complex delivery challenges, enabling better patient outcomes. The company operates out of 4 locations across India, USA and Canada.

Rubicon Research holds more than 50 issued patents in drug delivery technologies and its portfolio spans multiple dosage forms, including oral solids, oral liquids, nasal, ophthalmic, injectable, sterile, topical, drug device combinations, and fixed-dose combinations. Its flagship manufacturing facility at Ambernath has been inspected by leading global health authorities, including the US FDA and UK MHRA.

Rubicon Research is a portfolio company of General Atlantic, a global growth equity investor with USD 53 billion in assets under management.

For additional information, please visit www.rubicon.co.in or LinkedIn, Facebook, Twitter.

About Cipla
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT March’21), 3rd largest in the pharma private market in South Africa (IQVIA MAT March’21 ’20), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.

For queries, please contact:
Kermin Bhot
Email at: kermin.bhot@rubicon.co.in